ArticleJournal of neuroendocrinology2026
Mapping of oxytocin- and arginine vasopressin-expressing neurons with calbindin 1 or reelin in the male mouse brain.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oxytocin (OXT)- and arginine vasopressin (AVP)-synthesizing neurons are traditionally classified into magnocellular and parvocellular types based on their projection targets. However, molecular markers that reliably distinguish these neuronal subtypes across hypothalamic regions remain undefined. Recent single-cell transcriptomic studies suggest that Calb1 and Reln are differentially expressed in magnocellular and parvocellular OXT-synthesizing neurons in the hypothalamic paraventricular nucleus (PVN). Whether this molecular distinction extends to OXT neurons beyond the PVN or to AVP neurons has remained unclear. Fluorogold (FG) was administered to adult male C57BL/6J mice via tail vein injection. Calbindin 1 and reelin expression in OXT- and AVP-synthesizing neurons in the bed nucleus of the stria terminalis (BNST), PVN, supraoptic nucleus (SON), and retrochiasmatic supraoptic nucleus (SOR) was examined by immunocytochemistry. FG-labeled neurons were distributed in the PVN, SON, and SOR. Most OXT-immunoreactive (ir) neurons in the anterior PVN, SON, and SOR were FG-positive, whereas many OXT-ir neurons in the posterior PVN were FG-negative. Most FG-positive OXT-ir neurons showed calbindin 1 immunoreactivity. Two-thirds of FG-negative OXT-ir neurons in the posterior PVN expressed reelin. Almost all Reln-positive OXT-ir neurons were FG-negative. Nearly all AVP-ir neurons were FG-positive, and more than half expressed calbindin 1, whereas reelin expression was not detected. In corticotropin-releasing hormone (CRH)-Venus knock-in mice, AVP-ir neurons and CRH-positive neurons were not colocalized within the PVN, and AVP-ir and CRH-positive fibers were localized to distinct layers of the median eminence. These findings indicate that AVP expression in parvocellular CRH neurons was below the detection threshold of the methods used in this study. Calbindin 1 serves as a marker for magnocellular OXT neurons, whereas reelin identifies a subset of parvocellular OXT neurons. Given that the detected AVP-ir neurons were predominantly magnocellular, calbindin 1 labels a subset of this magnocellular AVP population. This molecular distinction provides a framework for distinguishing OXT- and AVP-expressing neuronal populations and for examining their respective roles in endocrine and behavioral regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.